Dermatofibrosarcoma Protuberans

What Is Dermatofibrosarcoma Protuberans

Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing malignant tumour that arises from the dermis, the thick layer of living tissue beneath the epidermis. It is classified as a soft-tissue sarcoma, a group of cancers that develop from connective tissues such as fat, muscle, nerves, and fibrous tissue. Although DFSP is malignant, it behaves differently from many other sarcomas because it rarely spreads to distant organs. Instead, its main danger lies in its ability to infiltrate deeply into surrounding structures, including fascia, muscle, and even bone, if left untreated.

The disease most often affects young and middle-aged adults, with a peak incidence between the ages of 20 and 50 years. It occurs slightly more frequently in males than in females and shows no strong racial predilection. The trunk, particularly the chest, back, and abdomen, is the most common site, followed by the proximal extremities such as the thighs and upper arms. Head and neck involvement is less frequent but well documented. Because of its indolent growth, patients may notice a lesion for months or even years before seeking medical attention.

Typical Clinical Appearance

The earliest sign is usually a firm, slightly raised plaque that feels rubbery or hard on palpation. The overlying skin may appear normal, slightly reddish-brown, or violaceous. Over time, the plaque expands laterally and develops nodular projections, giving rise to the term “protuberans” in its name. These nodules can become quite large, sometimes exceeding 10 centimetres in diameter, and may ulcerate if they outgrow their blood supply.

Several clinical variants have been described. The classic form presents as a multinodular plaque. The atrophic variant appears as a depressed, scar-like area with a wrinkled surface. The sclerosing variant feels extremely firm and woody due to dense collagen deposition. The pigmented variant, also known as Bednar tumour, contains melanin-producing dendritic cells and appears dark brown to black. The myxoid variant has a softer, gelatinous consistency because of abundant mucopolysaccharide matrix. Recognition of these variants is important because some, particularly the fibrosarcomatous type, carry a higher risk of aggressive behaviour.

Molecular Basis: The COL1A1–PDGFB Fusion

More than 90 percent of DFSP tumours harbour a characteristic genetic rearrangement that fuses two genes: COL1A1 on chromosome 17 and PDGFB on chromosome 22. In plain language, COL1A1 provides instructions for making type I collagen, a structural protein abundant in skin and connective tissue. PDGFB encodes platelet-derived growth factor B, a signalling protein that stimulates cell growth and division. The fusion places the strong, constantly active promoter of the collagen gene in front of the growth factor gene, causing the tumour cells to produce excessive amounts of PDGFB.

This overproduction creates an autocrine loop: the tumour cells secrete PDGFB, which then binds to its own receptors (PDGFR) on the same cells, driving continuous proliferation. The fusion arises either as a supernumerary ring chromosome containing the fused genes or as an unbalanced translocation between chromosomes 17 and 22, written as t(17;22)(q22;q13). Detection of this fusion by fluorescence in situ hybridisation (FISH) or reverse transcription polymerase chain reaction (RT-PCR) is a valuable diagnostic adjunct, especially in small biopsies where histology is ambiguous.

Local Invasion Versus Metastatic Potential

DFSP is notorious for its infiltrative growth pattern. Microscopic tumour extensions, often described as “tentacles,” project beyond the visible or palpable margins into the subcutaneous fat, fascia, and occasionally underlying muscle or bone. This behaviour explains the historically high recurrence rates after simple excision. Despite this locally aggressive phenotype, distant metastasis is uncommon, occurring in approximately 1 to 5 percent of cases. When metastasis does occur, the lungs are the most frequent site, followed by bone and regional lymph nodes.

The risk of metastasis increases significantly when the tumour undergoes fibrosarcomatous transformation, a histological progression marked by areas of high-grade spindle cell sarcoma resembling fibrosarcoma. Fibrosarcomatous DFSP (FS-DFSP) accounts for roughly 10 to 15 percent of cases and is associated with a metastatic rate of 15 to 20 percent. Other adverse features include deep muscular invasion, large tumour size (greater than 5 cm), and positive surgical margins after initial resection.

Diagnosis: Biopsy and Immunohistochemistry

Definitive diagnosis requires a tissue biopsy, preferably an incisional or core-needle biopsy that samples the deep portion of the lesion. Superficial shave biopsies often miss the diagnostic architecture because the tumour originates in the mid-to-deep dermis and extends downward. The pathologist looks for a monotonous proliferation of uniform spindle cells arranged in a characteristic “storiform” or cartwheel pattern, infiltrating the dermis and subcutis in a honeycomb or lace-like fashion between collagen bundles.

Immunohistochemistry plays a crucial confirmatory role. The tumour cells are consistently positive for CD34, a cell-surface glycoprotein normally expressed on vascular endothelial cells and certain progenitor cells. In the context of a spindle cell neoplasm of the skin, strong diffuse CD34 positivity strongly supports DFSP and helps distinguish it from mimics such as dermatofibroma (which is usually CD34 negative or only focally positive at the periphery), desmoid-type fibromatosis (beta-catenin nuclear positive, CD34 negative), and spindle cell melanoma (S100 and SOX10 positive). In fibrosarcomatous areas, CD34 expression may be lost, and the cells may show increased mitotic activity and nuclear atypia.

Treatment: Surgical Excision and Mohs Micrographic Surgery

Complete surgical removal with histologically negative margins is the cornerstone of curative treatment. Because DFSP extends microscopically far beyond clinical margins, traditional wide local excision with 2 to 3 centimetre clinical margins has been the standard, but this approach can result in large defects requiring complex reconstruction, especially on the trunk and proximal limbs.

Mohs micrographic surgery has emerged as a tissue-sparing alternative with comparable or superior cure rates. In this technique, the tumour is removed in thin layers, and each layer is processed with horizontal frozen sections that allow examination of 100 percent of the peripheral and deep margins. The surgeon maps any residual tumour and excises additional tissue only where needed. Published series report 5-year recurrence rates of 1 percent or less with Mohs surgery, compared with 10 to 20 percent after standard wide excision with narrower margins. Mohs is particularly advantageous for tumours on the head, neck, and hands where tissue conservation is critical.

For tumours that are unresectable without major functional loss, or for those with fibrosarcomatous transformation where adjuvant therapy may be considered, multidisciplinary discussion involving surgical oncology, radiation oncology, and medical oncology is recommended. Radiation therapy may be used postoperatively for close or positive margins when further surgery is not feasible, although its role remains less defined than in other soft-tissue sarcomas.

Systemic Therapy: Imatinib for Advanced Disease

The discovery of the COL1A1–PDGFB fusion provided a rational target for molecular therapy. Imatinib mesylate, a tyrosine kinase inhibitor that blocks PDGFR (as well as BCR-ABL and c-KIT), has demonstrated remarkable activity in DFSP. In clinical trials and expanded-access programmes, imatinib at a standard dose of 400 mg daily produced objective responses (partial or complete regression) in approximately 50 to 70 percent of patients with locally advanced, recurrent, or metastatic disease. Responses are often durable, lasting years in some cases.

Imatinib is indicated for adult patients with unresectable, recurrent, or metastatic DFSP. It is also used neoadjuvantly to shrink large tumours before planned resection, potentially converting an unresectable tumour into a resectable one and reducing the extent of surgery. Treatment is generally well tolerated; common side effects include periorbital oedema, nausea, muscle cramps, fatigue, and mild cytopenias. Monitoring includes regular complete blood counts and liver function tests. Resistance can develop, usually through secondary mutations in the PDGFR kinase domain, but this is less frequent than in gastrointestinal stromal tumours (GIST).

Fibrosarcomatous Transformation

Fibrosarcomatous DFSP (FS-DFSP) is defined by the presence of a high-grade fibrosarcomatous component comprising at least 5 to 10 percent of the tumour volume, although exact thresholds vary among pathologists. These areas show increased cellularity, marked nuclear atypia, and a mitotic rate typically exceeding 5 mitoses per 10 high-power fields. The storiform pattern gives way to a more fascicular or herringbone architecture reminiscent of adult-type fibrosarcoma.

Clinically, FS-DFSP behaves more aggressively. The metastatic rate rises to 15–20 percent, and the time to metastasis is shorter. CD34 immunoreactivity is often lost in the fibrosarcomatous areas, which can create diagnostic confusion with other high-grade spindle cell sarcomas. Molecular confirmation of the COL1A1–PDGFB fusion remains positive in both components, confirming their clonal relationship. Management of FS-DFSP follows the same surgical principles but with greater emphasis on achieving wide margins and stronger consideration of adjuvant radiation and systemic therapy with imatinib, especially if margins are positive or metastasis is present at diagnosis.

Recurrence and Long-Term Follow-Up

Local recurrence is the most common treatment failure, historically reported in 10 to 50 percent of cases after standard excision, depending on margin status. With Mohs surgery or wide excision with adequate margins, 5-year local control exceeds 95 percent. Recurrences typically appear within the first 3 years but can emerge a decade or more after initial treatment, mandating long-term surveillance.

Follow-up protocols generally involve clinical examination of the surgical site and regional lymph nodes every 6 to 12 months for at least 5 years, then annually thereafter. Imaging with chest radiography or computed tomography is reserved for patients with FS-DFSP, large deep tumours, or symptoms suggestive of metastasis. Patient education is essential: any new firm nodule, skin change, or persistent pain at the scar site should prompt immediate evaluation. Because DFSP can recur as a subtle induration within a scar, both patients and clinicians must maintain a low threshold for biopsy of suspicious changes.

Special Considerations in Pregnancy and Paediatric Populations

DFSP during pregnancy is rare but documented. Hormonal influences may accelerate growth, yet the fundamental biology remains unchanged. Surgical excision can often be deferred until after delivery if the tumour is not threatening vital structures, but each case requires individualised discussion. Imatinib is contraindicated in pregnancy due to teratogenicity observed in animal studies and case reports of congenital anomalies in humans.

Paediatric DFSP accounts for less than 5 percent of all cases. The clinical behaviour and molecular genetics are similar to adult disease. Treatment principles mirror those for adults, with a strong preference for Mohs surgery to minimise disfigurement during growth. Long-term functional and cosmetic outcomes are important considerations in children, and multidisciplinary care involving paediatric oncology, plastic surgery, and psychology is beneficial.

Differential Diagnosis: Clinical and Histological Mimics

Several benign and malignant entities can resemble DFSP clinically or histologically. Dermatofibroma (benign fibrous histiocytoma) is the most common mimic; it is usually smaller, more superficial, and dimples on lateral compression (the “dimple sign”). Histologically, it lacks the deep infiltrative growth and is CD34 negative or only peripherally positive. Desmoid-type fibromatosis infiltrates deeply but shows nuclear beta-catenin positivity and is CD34 negative. Atypical fibroxanthoma and pleomorphic dermal sarcoma occur on sun-damaged skin of elderly patients and show marked pleomorphism. Kaposi sarcoma is HHV-8 positive and vascular in nature. Spindle cell melanoma expresses S100, SOX10, and often HMB-45 or Melan-A. Metastatic spindle cell carcinoma expresses cytokeratins. A panel of immunohistochemical stains, combined with molecular testing when needed, reliably separates these entities.

Prognosis and Quality of Life

For the vast majority of patients with classic DFSP who achieve complete resection with negative margins, the prognosis is excellent. Disease-specific survival at 10 years exceeds 99 percent. The main determinants of outcome are histologic subtype (classic versus fibrosarcomatous), margin status, and anatomic site. Quality of life after treatment is generally good, although large excisions on the trunk or limbs can result in contour deformities, sensory changes, or functional impairment. Reconstructive techniques, including local flaps, skin grafts, and free tissue transfer, are often employed to optimise cosmetic and functional results. Psychological support may be helpful for patients coping with a cancer diagnosis, visible scarring, or the anxiety of prolonged surveillance.

Emerging Research and Future Directions

Ongoing research aims to refine risk stratification, optimise systemic therapy, and explore combination strategies. Next-generation sequencing has identified secondary mutations in TP53, RB1, and CDKN2A that may correlate with fibrosarcomatous progression and resistance to imatinib. Clinical trials are investigating the addition of checkpoint inhibitors, CDK4/6 inhibitors, and other tyrosine kinase inhibitors such as dasatinib and nilotinib for imatinib-resistant disease. Neoadjuvant imatinib trials seek to define the optimal duration of preoperative therapy and its impact on surgical margins and long-term outcomes. Liquid biopsy approaches targeting circulating tumour DNA with the COL1A1–PDGFB fusion are being explored for non-invasive monitoring of minimal residual disease and early detection of recurrence.

Key Points Summary

• DFSP is a rare, locally aggressive dermal sarcoma with low metastatic potential in its classic form.
• The hallmark genetic event is the COL1A1–PDGFB fusion, driving autocrine PDGFB signalling.
• Clinical presentation is a slow-growing firm plaque evolving into nodules, most often on the trunk of young adults.
• Diagnosis requires deep biopsy; CD34 positivity and molecular confirmation of the fusion are diagnostic.
• Mohs micrographic surgery offers the highest cure rates with maximal tissue preservation.
• Imatinib is effective for unresectable, recurrent, metastatic, or neoadjuvant settings.
• Fibrosarcomatous transformation increases metastatic risk and may reduce CD34 expression.
• Long-term follow-up is essential due to the risk of late local recurrence.

Resources

1. National Cancer Institute. Dermatofibrosarcoma Protuberans Treatment (PDQ®)–Health Professional Version. National Cancer Institute; 2024. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/dermatofibrosarcoma-protuberans-treatment-pdq Accessed: 27 August 2026.
2. American Cancer Society. Dermatofibrosarcoma Protuberans. American Cancer Society; 2023. Available at: https://www.cancer.org/cancer/soft-tissue-sarcoma/about/dermatofibrosarcoma-protuberans.html Accessed: 27 August 2026.
3. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024. National Comprehensive Cancer Network; 2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf Accessed: 27 August 2026.
5. Moinfar F, et al. Dermatofibrosarcoma protuberans: clinicopathologic and molecular analysis of a series of 51 cases. Modern Pathology. 2000;13(8):863-871.
6. Siegel JA, et al. Imatinib mesylate for the treatment of dermatofibrosarcoma protuberans: a systematic review. Journal of the American Academy of Dermatology. 2018;79(4):701-709.e5.
7. Kazakov DV, et al. Dermatofibrosarcoma protuberans: a clinicopathological and molecular genetic study of 100 cases with long-term follow-up. American Journal of Surgical Pathology. 2015;39(7):921-932.
8. Schaefer IM, et al. Molecular pathology of dermatofibrosarcoma protuberans. Diagnostic Pathology. 2017;12:78.
9. Hirsch D, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans: a meta-analysis of recurrence rates. Journal of the American Academy of Dermatology. 2019;80(2):456-463.
10. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced dermatofibrosarcoma protuberans: results of a phase II trial. Journal of Clinical Oncology. 2009;27(30):5070-5075.
11. World Health Organization / International Agency for Research on Cancer. Soft Tissue and Bone Tumours: WHO Classification of Tumours. 5th edition. Lyon: IARC; 2020.
12. American Academy of Dermatology. Dermatofibrosarcoma Protuberans: Diagnosis and Treatment. American Academy of Dermatology; 2023. Available at: https://www.aad.org/diseases/skin-cancer/dermatofibrosarcoma-protuberans Accessed: 27 August 2026.